Views & Analysis Many millions still untreated – but hep C boom is already ov... Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
News NHS under fire for rationing hep C drugs NHS England tried to interfere with NICE appraisals, says BMJ.
US Gilead hopes cut-price pan-genomic hep C combo will revive s... Epclusa is first treatment for all six major virus genotypes.
News EU regulators back new Hep C combo pills Two new hepatitis C combination drugs from Gilead and Merck Sharp and Dohme (MSD), that negate the need for interferon therapy and its hated side effects, have been recommended for approval
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
